Rebecca’s PhD aims to turn innovative synthetic biology into practical solutions that can benefit society

 
 
 

For Rebecca’s PHD, she worked with Fujifilm Diosynth Biotechnologies on Novel insulators that can enhance and sustain transgene production. In this case study, Rebecca shares her desire to help guide and inspire as well and discussing how advancements in synthetic biology have the potential to revolutionize IB.

Why did you decide to undertake this project?

I have a profound interest in gene regulation and the epigenetic mechanisms that control transgene expression. Investigating novel insulators and their potential to sustain transgene expression not only advances our understanding of gene regulation but also addresses the practical necessity for stable transgene expression in critical fields such as gene therapy, biotechnology, and genetic engineering.

Collaborating with Fujifilm Diosynth Biotechnologies affords me access to unparalleled expertise, cutting-edge technical resources, and invaluable industry exposure, all of which are essential for driving forward this innovative research.

What are your ambitions for the future?

My ambition is to stay at the leading edge of biotechnology research, with a focus on epigenetic therapies and gene expression stability. I enjoy solving complex problems and leveraging innovative thinking to drive advancements in this field. I would like to further my bioinformatic skills and apply them to enhance our understanding and capabilities. As my career progresses, I aspire to take on leadership roles to guide and inspire teams, fostering a collaborative and forward-thinking environment.

What excites you about your research?

I am particularly excited by my project because it translates innovative synthetic biology into practical solutions that can benefit society and address specific problems within the biopharmaceutical industry.  My research contributes to advancements in the manufacturing of therapeutic proteins, vaccines, and other biologics, ultimately resulting in more effective and accessible treatments for patients.


Where/what do you think the next innovation in IB will be? 

Continued advancements in synthetic biology techniques and genetic engineering tools have the potential to revolutionize IB. This encompasses the engineering of microorganisms and cells to produce high-value compounds such as biofuels, specialty chemicals, and pharmaceuticals. Innovations in DNA synthesis, genome editing technologies like CRISPR-Cas9, and metabolic engineering strategies are likely to play a pivotal role in driving these developments, enhancing the efficiency, scalability, and sustainability of bioproduction processes.

What is an interesting fact about you / what do you enjoy doing away from your studies?

An interesting fact about me is that I am an enthusiastic runner who completed my first ultramarathon last year. I also enjoy bouldering, hiking, and reading.

PhDAndrew Bonnar